PTC Therapeutics, Inc.
PTCT
$66.71
$2.223.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.73B | 1.78B | 1.76B | 1.77B | 806.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.73B | 1.78B | 1.76B | 1.77B | 806.78M |
| Cost of Revenue | 502.26M | 503.24M | 559.56M | 582.84M | 591.88M |
| Gross Profit | 1.23B | 1.28B | 1.21B | 1.19B | 214.90M |
| SG&A Expenses | 347.14M | 334.95M | 324.36M | 308.60M | 300.91M |
| Depreciation & Amortization | 24.74M | 18.70M | 14.20M | 13.01M | 60.74M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 874.15M | 856.89M | 898.12M | 904.45M | 953.53M |
| Operating Income | 856.51M | 922.26M | 866.81M | 868.31M | -146.75M |
| Income Before Tax | 696.62M | 741.00M | 666.09M | 651.41M | -363.12M |
| Income Tax Expenses | 13.98M | -10.72M | 36.91M | 56.56M | 176.00K |
| Earnings from Continuing Operations | 682.64 | 751.72 | 629.17 | 594.84 | -363.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 682.64M | 751.72M | 629.17M | 594.84M | -363.30M |
| EBIT | 856.51M | 922.26M | 866.81M | 868.31M | -146.75M |
| EBITDA | 895.32M | 954.94M | 894.86M | 895.80M | -71.08M |
| EPS Basic | 8.79 | 9.61 | 8.02 | 7.56 | -4.73 |
| Normalized Basic EPS | 5.47 | 6.99 | 6.43 | 6.38 | -1.77 |
| EPS Diluted | 7.73 | 8.55 | 6.97 | 6.50 | -4.74 |
| Normalized Diluted EPS | 4.78 | 6.30 | 5.72 | 5.67 | -1.77 |
| Average Basic Shares Outstanding | 315.43M | 311.94M | 310.39M | 308.97M | 307.35M |
| Average Diluted Shares Outstanding | 332.34M | 328.85M | 318.66M | 317.24M | 307.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |